Iris Noordhoek

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy

Iris Noordhoek, Kai Treuner, Hein Putter et al. · Clinical Cancer Research · 2020 · 133 citations · Full text

Medicine, Endocrinology, Oncology +17

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials

Iris Noordhoek, Erik J. Blok, Elma Meershoek‐Klein Kranenbarg et al. · Journal of Clinical Oncology · 2020 · 43 citations · Full text

Medicine, Oncology, Breast Oncology +15

Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer

Betül Ünlü, Begüm Kocatürk, Araci M. R. Rondon et al. · Oncogene · 2022 · 22 citations · Full text

Medicine, Cancer Biology, Cell Biology +17

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg et al. · Journal of Clinical Oncology · 2022 · 20 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study

Iris Noordhoek, Esther Bastiaannet, N.A. de Glas et al. · Journal of Geriatric Oncology · 2022 · 17 citations · Full text

Medicine, Geriatric Medicine, Oncology +17